Use of the CA 125 Algorithm for the Early Detection of Ovarian Cancer in Low Risk Women
Phase NA Recruiting
8,000 enrolled
NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer
Phase 1 Recruiting
24 enrolled
Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study)
Phase 2 Recruiting
30 enrolled
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
Phase 3 Recruiting
360 enrolled
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Phase 2 Recruiting
2,900 enrolled
HOTT
Phase 3 Recruiting
220 enrolled
Spanish Decision Tool for Ovarian Cancer Maintenance Therapy
Phase NA Recruiting
70 enrolled
DETECTR
Recruiting
1,000 enrolled
TroFuse-022
Phase 3 Recruiting
770 enrolled
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer
Phase 3 Recruiting
336 enrolled
MAESTRA 2
Phase 3 Recruiting
466 enrolled
PSI-Immune
Phase 2 Recruiting
880 enrolled
A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
Phase 1 Recruiting
76 enrolled
A Study of Isoquercetin in People With Ovarian Cancer
Phase 2 Recruiting
90 enrolled
TroFuse-021
Phase 3 Recruiting
900 enrolled
The Impact Of A Patient Support Community On Patients With Neuroendocrine Cervical Cancer: NECC Peer Support
Recruiting
25 enrolled
Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF
Phase 1 Recruiting
300 enrolled
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
Phase 2 Recruiting
89 enrolled
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
Phase 1 Recruiting
54 enrolled
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
Phase 2 Recruiting
81 enrolled
DENALI
Phase 2 Recruiting
310 enrolled
Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study
Phase NA Recruiting
100 enrolled
Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma
Phase 1/2 Recruiting
37 enrolled
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
Phase 1 Recruiting
450 enrolled
A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
Phase 1 Recruiting
45 enrolled
ANTARES
Phase 2 Recruiting
28 enrolled
Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments
Phase 1/2 Recruiting
350 enrolled
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
Phase 1 Recruiting
132 enrolled
A Phase III Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy Versus Placebo Combined With Concurrent Chemoradiotherapy for the Treatment of Locally Advanced Cervical Cancer
Phase 3 Recruiting
720 enrolled
A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
Phase 1 Recruiting
145 enrolled
A Bidirectional Cohort Study on Prophylactic Resection Surgery in Populations at Moderate-to-High Risk for Hereditary Ovarian Cancer
Recruiting
480 enrolled
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
Recruiting
1,100 enrolled
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
Phase 2 Recruiting
285 enrolled
Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies
Phase 1 Recruiting
60 enrolled
Study of INCB123667 in Subjects With Advanced Solid Tumors
Phase 1 Recruiting
604 enrolled
A Study of XMT-1660 in Participants With Solid Tumors
Phase 1 Recruiting
319 enrolled
PAROLA
Phase 3 Recruiting
510 enrolled
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
Phase 2 Recruiting
393 enrolled
Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells
Phase 1 Recruiting
27 enrolled
INDIGO
Phase NA Recruiting
11,200 enrolled
OCTOPOD
Phase 1/2 Recruiting
44 enrolled
Act4CC
Phase NA Recruiting
800 enrolled
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
Phase 2 Recruiting
140 enrolled
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
Phase 2 Recruiting
270 enrolled
MAESTRA 1
Phase 2 Recruiting
160 enrolled
ACTengine
Phase 1/2 Recruiting
375 enrolled
Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations
Phase 2 Recruiting
36 enrolled
Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer
Phase 1 Recruiting
42 enrolled
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
Phase 1 Recruiting
51 enrolled
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
Phase 1/2 Recruiting
949 enrolled